Givosiran

Discussion in 'Alnylam Pharmaceuticals' started by anonymous, Nov 13, 2019 at 10:50 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest


  2. anonymous

    anonymous Guest

    JG,

    Your panties are showing. Man, we ALL know that this is you responding. Please, can you just walk away from the computer? Surely your espionage classes at the Academy drummed some sense into your head? This isn't the best approach....
     
  3. anonymous

    anonymous Guest

  4. anonymous

    anonymous Guest

    apparently your reading comprehension is challenged, JG. The DMC met to review neuropathy signals, but the study was stopped due to “a benefit risk profile that no longer supported dosing.” That was the excess mortality. The company would never see any data prior to unblinding.

    Following recent reports in the Phase 2 OLE study of new onset or worsening peripheral neuropathy, the ENDEAVOUR DMC assembled yesterday at the Company's request to review these reports and ENDEAVOUR data on an unblinded basis. The DMC did not find conclusive evidence for a drug-related neuropathy signal in the ENDEAVOUR trial, but informed the Company that the benefit-risk profile for revusiran no longer supported continued dosing. The Company subsequently reviewed unblinded ENDEAVOUR data which revealed an imbalance of mortality in the revusiran arm as compared to placebo.
     
  5. anonymous

    anonymous Guest

    Perfect example of the unwillingness to accept limitations of RNAi therapy and the reality of the underlying and unanswered safety concerns.
     
  6. anonymous

    anonymous Guest

    Look at our stock you worthless POS. Clearly we know what we are doing and the plan is working.

    I think you have gone silent because your options have jumped and all of a sudden everything is fine.

    Loser
     
  7. anonymous

    anonymous Guest

    better take the money and run. just a matter of time before promotion tactics are revealed and/or people start dropping like due to cardiac issues. think about it, even in our own internal KOL presentations, the doctors who speak say they have no idea what the downstream effect of “shutting of the faucet” for these proteins will have on patients.
     
  8. anonymous

    anonymous Guest

    Ok, I have to call you out. Please stop baiting him! He's proven that he can't help himself. You've made your point.
     
  9. anonymous

    anonymous Guest

    What is the salary range for these positions?
     
  10. anonymous

    anonymous Guest

    current range is $150-175K
     
  11. anonymous

    anonymous Guest

    Stop spreading lies, competitor swine! My offer was significantly higher.
     
  12. anonymous

    anonymous Guest

    Car allowance? Sign-on bonus or stock?
     
  13. anonymous

    anonymous Guest

    You trolls who are being so negative - go pound sand. Go back to primary care - Alnylam does more for patients then you have ever done. It's so foul that anyone would come here - complain about what this company has invested. No company is perfect however if you are miserable here - take your toxic entitlement somewhere else.
     
  14. anonymous

    anonymous Guest

    So true.